Zerenex Molecular has launched a new collection of over 4000 diverse and unique compounds within the Novel Chemical Entities - NCET collection
These heterocyclic (small (hetero) cyclic (fused) ring compounds with one or more chemical handles) such as imidazoles, pyridines, pyrazines etc as well as a variety of alycyclic (piperizines, piperidines) and aromatic compounds will continue to assist medicinal and synthetic chemists globally in developing hit generation and hit-to-lead optimisation libraries.
Using innovative chemistry, the company has designed, synthesised and acquired a variety of unique building blocks, key to creating diversity and novelty in drug discovery programmes.
Since its inception Zerenex Molecular continues to develop and strengthen its global reputation for specialising in the synthesis and supply of rare small molecule compounds to the pharmaceutical and biotech industries.
Zerenex Molecular is a dedicated supplier of unique research chemicals (building blocks, screening compounds, natural products and APIs) as well as a specialist provider of integrated drug discovery solutions to the life science industry.
Zerenex Molecular specialises in early stage proof-of-concept (POP) projects to validate biological hypotheses, validation of screening hits for exploratory medicinal chemistry (hit-to-lead), intermediates for expediting med chemistry SAR campaigns, drug candidates for in vivo studies, reference agents for bio-profiling, reference metabolites,building blocks for combinatorial chemistry, key intermediates for pharmaceuticals, and key intermediates for biomaterial and biosensor applications.
